16.03.2015 21:10:35
|
Valeant Announces $1.45 Bln Stock Offering
(RTTNews) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) said Monday that it has filed with the U.S. Securities and Exchange Commission a preliminary prospectus supplement to its effective shelf registration statement on Form S-3 in connection with a registered offering in the United States of $1.45 billion of its common shares.
The company will also grant to the underwriter of the offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.
The company expects to use the net proceeds of the offering, together with borrowings under the company's incremental term loan facilities, the proceeds of an offering of the company's senior notes and cash on hand, to fund the purchase price of the previously announced acquisition of Salix Pharmaceuticals, Ltd. (SLXP), as well as repayments of indebtedness of Salix and certain transaction expenses. The company plans to use any remaining proceeds for general corporate purposes, including acquisitions and debt repayments.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Valeant Pharmaceuticals Internationalmehr Nachrichten
Keine Nachrichten verfügbar. |